Market Overview

Aurora Cannabis Issues Below-Consensus Q2 Revenue Guidance

Share:
Aurora Cannabis Issues Below-Consensus Q2 Revenue Guidance

Canadian cannabis producer Aurora Cannabis Inc (NYSE: ACB)'s shares were trading lower Tuesday after the company issued below-consensus revenue guidance for the fiscal second quarter.

What Happened

The company said it expects to report revenue between $50 million and $55 million for the fiscal second quarter ended Dec. 31. This figure is higher than than the $11.7 million posted for the same period last year and the $29.7 million reported in the previous quarter. 

The expected revenue is significantly lower than the $67 million analysts were projecting. 

Learn, connect or raise money at the Cannabis Capital Conference, the leading event for connecting cannabis companies to investors.

Why It's Important

On Oct. 17, Canada legalized marijuana for recreational use, and Tuesday's guidance is Aurora's first to reflect the country's legal weed market. The company said the increase in its second-quarter revenue was due to the launch of the adult-use market in Canada and shipments of medical marijuana to around 71,000 patients.

Aurora said it's reached a production capacity of around 100,000 kilograms — approximately 220,500 pounds — per year, up from 70,000 kilograms in November.

What's Next

Aurora is scheduled to release its Q2 report Feb. 11.

The company  indicated it plans to increase production capacity to 150,000 kilograms by the end of the current quarter. 

Aurora shares were down 3.52 percent at $5.08 at the time of publication Tuesday. 

Related Links:

Aurora Cannabis Invests $7.5M In Alberta Marijuana Company High Tide

10 Reasons To Attend Benzinga's 2019 Cannabis Capital Conference

Posted-In: Aurora Cannabis Aurora Cannabis Earnings cannabis in CanadaCannabis News Guidance Markets Best of Benzinga

 

Related Articles (ACB)

View Comments and Join the Discussion!

Today's Pickup: Port Operator Secures $1 Per Gallon Natural Gas Deal For New Trucks

Trucking Companies Exposed To New Liability Risk After FMCSA Preemption